EGFR and hepatocellular carcinoma: Significantly, the present study uncovered an uncharacterized mechanism by which 14-3-3-σ contributes to anoikis resistance in HCC cells, likely by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 pathway.